Ascendis Pharma A/S
ASNDHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeAscendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The $17.62B market capitalization puts ASND squarely in large-cap range for its industry. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.
Market Cap
$17.62B
Beta
—
P/E (TTM)
30.76
P/E (Fwd)
25.83
EPS (TTM)
$8.73
EPS (Fwd)
$10.40
ROE
332.6%
ROA
-0.6%
Cash
$572.8M
Total Debt
$896.7M
Free CF
$118.2M
52W Change
53.1%
Annual Financials
Cash vs Debt
On the balance sheet, ASND has $572.8M in cash with $896.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $118.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 332.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $51.2M (2022) to $720.1M (2025), reflecting a 1307% increase over the period.
Investors considering Ascendis Pharma A/S should weigh the typical risks associated with ASND's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ascendis Pharma A/S's trajectory.